Scholarlink

Purpose <p>This study evaluates the survivorship and clinical outcomes of revision total hip arthroplasty (THA) to treat symptomatic leg length discrepancy (LLD) via limb shortening.</p> Methods <p>A total of ten patients were included who underwent revision THA to treat LLD via limb shortening at a single arthroplasty center from January 1, 2000, to December 31, 2022, representing 0.4% (ten of 2763) of all revision THA during this period. Among these cases, six of ten (60.0%) were men, mean age at index surgery was 62&#xa0;years (range, 39 to 81), and mean follow-up was 7.63&#xa0;years (range, 3.51 to 15.73). Kaplan–Meier survivorship analysis was conducted with failure defined as revision surgery for any reason.</p> Results <p>Kaplan–Meier survivorship for failure due to any cause was 100.0% at five years, with nine hips at risk and 80.0% at ten and 15&#xa0;years with one hip at risk. One patient failed due to dislocation. The mean LLD significantly improved from a pre-operative value of 24.5&#xa0;mm (SD 7.25) to a post-operative value of 1.25&#xa0;mm (SD 3.17) (<i>P</i> &lt; 0.001). There was a significant increase in Harris hip scores from 50.44 (SD 11.11) pre-operatively to 75.4 (SD 19.35) at one year (<i>P</i> = 0.0172) and 84.6 (SD 12.44) at three years post-operatively (<i>P</i> = 0.011).</p> Conclusion <p>Revision total hip arthroplasty to treat LLD via limb shortening provides favourable 5- to 10-year survivorship and clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Revision total hip arthroplasty with limb shortening for symptomatic leg length discrepancy: survivorship and clinical outcomes at mean seven-year follow-up

  • 期刊论文

  • 发表日期：

    2026年6月3日

查看全文
  • Faran Chaudhry,
  • Adam Bridger,
  • Anser Daud,
  • Arieh Greenberg,
  • Oleg Safir,
  • Allan Gross,
  • Paul Kuzyk

摘要

Purpose

This study evaluates the survivorship and clinical outcomes of revision total hip arthroplasty (THA) to treat symptomatic leg length discrepancy (LLD) via limb shortening.

Methods

A total of ten patients were included who underwent revision THA to treat LLD via limb shortening at a single arthroplasty center from January 1, 2000, to December 31, 2022, representing 0.4% (ten of 2763) of all revision THA during this period. Among these cases, six of ten (60.0%) were men, mean age at index surgery was 62 years (range, 39 to 81), and mean follow-up was 7.63 years (range, 3.51 to 15.73). Kaplan–Meier survivorship analysis was conducted with failure defined as revision surgery for any reason.

Results

Kaplan–Meier survivorship for failure due to any cause was 100.0% at five years, with nine hips at risk and 80.0% at ten and 15 years with one hip at risk. One patient failed due to dislocation. The mean LLD significantly improved from a pre-operative value of 24.5 mm (SD 7.25) to a post-operative value of 1.25 mm (SD 3.17) (P < 0.001). There was a significant increase in Harris hip scores from 50.44 (SD 11.11) pre-operatively to 75.4 (SD 19.35) at one year (P = 0.0172) and 84.6 (SD 12.44) at three years post-operatively (P = 0.011).

Conclusion

Revision total hip arthroplasty to treat LLD via limb shortening provides favourable 5- to 10-year survivorship and clinical outcomes.